Semaglutide linked to transient CA 19-9 and CA-125 tumor biomarker elevation in patient

GLP-1 receptor agonists like semaglutide are highly effective for type 2 diabetes and obesity, improving glycemic control and promoting weight loss. However, concerns exist regarding their potential impact on cancer risk, particularly the known preclinical finding of thyroid C-cell tumors in rodents. While these findings haven't translated to human thyroid cancer risk in clinical trials, the broader influence of GLP-1 agonists on other tumor biomarkers remains an area requiring careful observation. Elevated tumor biomarkers such as CA 19-9 and CA-125 typically raise suspicion for pancreatic, biliary, or ovarian malignancies, often leading to extensive and invasive diagnostic workups. Understanding if semaglutide can transiently affect these markers is crucial to prevent unnecessary patient anxiety and medical procedures.

This clinical case report details a 61-year-old female patient undergoing Semaglutide treatment. She was referred for gynecological consultation due to suspected adnexal cysts following an MRI for a functional defecation disorder. The initial workup included a gynecological examination and transvaginal ultrasound. Subsequently, tumor biomarker testing for CA 19-9 and CA-125 was performed. Following initial elevated results, the patient underwent further investigations to rule out neoplastic origins, specifically involving the pancreas or biliary tract. Biomarker levels were re-evaluated at one month and two months post-initial elevation to monitor their trajectory.